Black Stone Minerals (BSM): Strong Industry, Solid Earnings Estimate Revisions

One stock that might be an intriguing choice for investors right now is Black Stone Minerals, L.P. BSM. This is because this security in the Energy and Pipeline - Master Limited Partnerships space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.

This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Energy and Pipeline - Master Limited Partnerships space as it currently has a Zacks Industry Rank of 39 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.

Meanwhile, Black Stone Minerals is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.

Black Stone Minerals, L.P. Price and Consensus

Black Stone Minerals, L.P. price-consensus-chart | Black Stone Minerals, L.P. Quote

In fact, over the past month, current quarter estimates have risen from 29 cents per share to 33 cents per share, while current year estimates have risen from $1.20 per share to $1.32 per share. This has helped BSM to earn a Zacks Rank #2 (Buy), further underscoring the company’s solid position. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

So, if you are looking for a decent pick in a strong industry, consider Black Stone Minerals. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.